Immuno-polymeric Drugs For Prostate Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$626,995.00
Summary
Prostate cancer is the most common cancer in men over 50 and the second most frequent cause of cancer deaths in Western society. Docetaxel is the first line of chemotherapy when other intervention strategies are unsuccessful, but 30% of patients suffer from severe side-effects. To address this problem, we will utilise carriers for docetaxel that directly target prostate tumours using a novel antibody approach. This increases accumulation at the tumour site while decreasing off-target toxicity.
Characterisation Of Two Novel Markers Of Osteosarcoma Metastasis As Potential Therapeutic Targets
Funder
National Health and Medical Research Council
Funding Amount
$624,500.00
Summary
Osteosarcoma (OS) is the most common bone tumour in children and adolescents. In spite of aggressive chemotherapy, OS tumours that metastasise to the lungs result in dismal long-term survivals of only 10-20%. For these patients, new treatment options are desperately needed. In this proposal we show compelling data identifying two new markers of OS metastasis. This research aims to validate the suitability of these novel markers as therapeutic targets to prevent OS metastasis.
Developing And Applying Statistical Genetics Methods To Identify Genes, Molecular Biomarkers And Environmental Agents That Causally Affect Risk Of Complex Musculoskeletal Diseases
Funder
National Health and Medical Research Council
Funding Amount
$707,370.00
Summary
My aim is to identify genes, biological molecules and environmental factors that causally affect risk of osteoporosis and ankylosing spondylitis (a form of autoimmune arthritis) using novel and existing statistical genetics methodologies. My research will advance understanding of the causes of these diseases, identify new opportunities for their treatment, and provide the scientific community with new statistical methods and software to identify factors that causally influence risk of disease.
Centre Of Research Excellence In Medicines Intelligence
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
The NHMRC Centre of Research Excellence in Medicines Intelligence is a co-ordinated research program that will accelerate the development and translation of evidence on prescribed medicines use and outcomes for regulators and payers. The CRE is perfectly placed to embrace the national ‘call to action’ from the Health Minister's recent announcement to establish Quality Use of Medicine Safety as a National Health Priority.
Most eye diseases have a genetic contribution, whether rare disorders affecting children such as retinoblastoma or congenital cataracts through to common disorders of older people such as myopia, age-related macular degeneration or glaucoma. We will continue our successful research to find genes that cause these diseases and use this to improve patient care and prevent blindness. We will work out how families can use this genetic information to participate in trials to develop new treatments.
An Investigation Of The Involvement Of Clotting Factors In Abdominal Aortic Aneurysm (AAA) Progression Within A Mouse Model
Funder
National Health and Medical Research Council
Funding Amount
$189,401.00
Summary
Early stage weakening of the main abdominal artery is present in ~100,000 Australians and currently has no accepted therapy. Development of drug therapies which limit progression of the weakening process is urgently needed. In this study involvement of the clotting cascade in artery weakening will be investigated. The study have been planned in order to identify new strategies which can be developed as treatments for artery weakening in patients.
KLK4 Is A Master Regulator Of Tumour Microenvironment Remodelling In Prostate Cancer And Bone Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$596,305.00
Summary
The current biomarker for prostate cancer, PSA, belongs to a large family of related proteins called KLK enzymes. We have evidence that one of these enzymes, KLK4, regulates many different pathways involved in tumour spreading especially to bones. This project will determine the specific components involved with a view to finding better biomarkers of tumour spread and bone metastasis and designing better treatments for these aspects of the disease.
Nitrogen Removal in Wastewater Treatment Using the Nitrite Pathway. Nitrogen removal from our wastewater is becoming very important in most parts of Australia to protect our unique aquatic environment. This removal is achieved biologically through two steps: Nitrification converts ammonium via nitrite to nitrate; and denitrification converts nitrate via nitrite again to harmless nitrogen gas. This project aims to develop a method that allows this process to go just via nitrite, instead of nitrat ....Nitrogen Removal in Wastewater Treatment Using the Nitrite Pathway. Nitrogen removal from our wastewater is becoming very important in most parts of Australia to protect our unique aquatic environment. This removal is achieved biologically through two steps: Nitrification converts ammonium via nitrite to nitrate; and denitrification converts nitrate via nitrite again to harmless nitrogen gas. This project aims to develop a method that allows this process to go just via nitrite, instead of nitrate, to nitrogen gas. This would significantly reduce oxygen and/or carbon requirement in nitrogen removal. If successful, the new operating method will allow modern wastewater treatment plants to achieve a better effluent quality at lower costs.Read moreRead less